The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat (lub 12-17 lat po zgodzie komisji bezpieczeństwa)
- •Zaawansowany lub rozszczepiony nowotwór litego z mutacją TP53 Y220C
- •Ogólny stan zdrowia ECOG 0 lub 1
- •Wcześniejsze leczenie przeciwnowotworowe z progresją choroby
- •Prawidłowe funkcjonowanie organów wewnętrznych
- •Mierzalne ogniska nowotworu (faza 2)
- •Brak wcześniejszego leczenia lekami anty-PD-1/PD-L1 lub progresja po takim leczeniu (faza 1b)
- •Mierzalne ogniska choroby (faza 1b)
✗ Disqualifies
- •Chemioterapia w ciągu 21 dni przed badaniem
- •Radioterapia w ciągu 14 dni przed badaniem
- •Pierwotny nowotwór mózgu
- •Historia zapalenia opon mózgowych lub ucisku rdzenia kręgowego
- •Przerzuty do mózgu, jeśli pacjent wymaga sterydów do ich leczenia
- •Udar lub przemijający zawał mózgu w ciągu 6 miesięcy
- •Choroby serca: niestabilna dławica piersiowa, niekontrolowane nadciśnienie, zawał w ciągu 6 miesięcy, niewydolność serca, arytmie
- •Aktywne zapalenie wątroby typu B lub C lub zakażenie HIV
Simplified criteria — AI translation
Trial details
- Minimum age
- 12 Years
- Last updated (source)
- June 26, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (77)
University of California Irvine Chao Family Comprehensive Cancer Center
Irvine, United States
University of San Diego Moores Cancer Center
La Jolla, United States
UCLA Jonsson Comprehensive Cancer Center
Los Angeles, United States
USC Norris Comprehensive Cancer Center
Los Angeles, United States
Rocky Mountain Cancer Center
Denver, United States
Yale Cancer Center
New Haven, United States
Medical Oncology Hematology Consultants
Newark, United States
University of Miami - Sylvester Comprehensive Cancer Center
Miami, United States
Advent Health
Orlando, United States
Florida Cancer Specialists South
Port Charlotte, United States
Massachusetts General Hospital
Boston, United States
Dana Farber Cancer Institute
Boston, United States
Karmanos Cancer Institute
Detroit, United States
University of Nebraska Medical Center Buffet Cancer Center
Omaha, United States
Memorial Sloan Kettering
New York, United States
Duke University
Durham, United States
The Cleveland Clinic Taussig Cancer Center
Cleveland, United States
University of Oklahoma
Oklahoma City, United States
Oregon Health & Science University (OHSU)
Portland, United States
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, United States
University of Pittsburgh Medical Center
Pittsburgh, United States
WellSpan York Cancer Center
York, United States
Medical University of South Carolina
Charleston, United States
Sarah Cannon Research Institute
Nashville, United States
New Experimental Therapeutics - NEXT Oncology
Austin, United States
Texas Oncology
Bedford, United States
UTSW - Moody Outpatient Center - Parkland Health
Dallas, United States
UT Southwest Simmons Cancer Center
Dallas, United States
The University of Texas MD Anderson Cancer Center
Houston, United States
New Experimental Therapeutics of San Antonio - NEXT Oncology
San Antonio, United States
Virginia Cancer Specialists
Fairfax, United States
University of Washington, Fred Hutchinson Cancer Center
Seattle, United States
University of Wisconsin Carbone Cancer Center
Madison, United States
Chris O'Brien Lifehouse Hospital
Camperdown, Australia
Mater Cancer Care Centre
South Brisbane, Australia
Flinders Medical Center
Bedford Park, Australia
Monash Medical Centre
Clayton, Australia
Linear Clinical Research
Nedlands, Australia
ICANS - Institut de cancérologie Strasbourg Europe
Strasbourg, France
Institut Bergonie
Bordeaux, France
Institut Claudius Regaud
Toulouse, France
EDOG Institut de Cancerologie de l'Ouest
Saint-Herblain, France
Centre Jean Perrin
Clermont-Ferrand, France
Institut Gustave Roussy
Villejuif, France
Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer
Lyon, France
CHU de Nîmes
Nîmes, France
Institute Cancer De Lorraine
Vandœuvre-lès-Nancy, France
Nationale Centrum für Tumorerkrankungen (NCT) Heidelberg
Heidelberg, Germany
Universitätsklinikum Augsburg
Augsburg, Germany
Asklepios Klinik Altona
Hamburg, Germany
Universitätsklinikum Frankfurt
Frankfurt am Main, Germany
Universitätsklinikum Essen
Essen, Germany
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rome, Italy
Istituti Fisioterapici Ospitalieri - Istituto Nazionale Tumori Regina Elena
Rome, Italy
ASST Grande Ospedale Metropolitano Niguarda
Milan, Italy
Fondazione IRCCS Istituto Nazionale Dei Tumori
Milan, Italy
Istituto Europeo Di Oncologia
Milan, Italy
Istituto Clinico Humanitas
Rozzano, Italy
Fondazione del Piemonte per l'Oncologia (IRCCS)
Candiolo, Italy
Humanitas San Pio X
Milan, Italy
IRCCS - lstituto Nazionale Tumori - Fondazione G. Pascale
Naples, Italy
National University Hospital
Kent Ridge, Singapore
National Cancer Center of Singapore
Singapore, Singapore
Asan Medical Center
Seoul, South Korea
National Cancer Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Seoul University Hospital
Seoul, South Korea
Severance Hospital Yonsei University
Seoul, South Korea
START MADRID_Hospital Universitario Fundacion Jimenez Diaz
Madrid, Spain
START MADRID_Hospital Universitario HM Sanchinarro - CIOCC
Madrid, Spain
Instituto de Investigacion Oncologica Vall d'Hebron (VHIO) - EPON
Barcelona, Spain
NEXT Oncology-Hospital Quironsalud Barcelona
Barcelona, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
START Rioja
Rioja, Spain
Hospital Clinico Universitario de Valencia
Valencia, Spain
Sarah Cannon Research Institute UK
London, United Kingdom
Freeman Hospital
Newcastle upon Tyne, United Kingdom
Trial contact
PMV Pharma Clinical Study Information Center
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.